SlideShare una empresa de Scribd logo
1 de 33
Descargar para leer sin conexión
Systemic Lupus
Erythematous
(SLE)
20
22
20
22
Lupus
clinical
case
Systemic
lupus
erythematosus
(SLE)
Lupus
clinical
case
Systemic
lupus
erythematosus
(SLE)
Introduction
20
22
20
22
● Systemic Lupus Erythematosus (SLE), or lupus, is an autoimmune
disorder where the immune system produces antibodies that
attack the body’s own tissues, causing inflammation in many
different parts of the body such as the skin, joints, brain, lungs,
heart and kidneys.
● SLE predominantly affects women between 12 and 45 (frequently
starting at childbearing age)
INTRODUCTION
Epidemiology
● Female:Male = 9:1
● About 90% of SLE sufferers are women while about 10% are men and children.
● About 90% of women with SLE are in their childbearing years, within the range of 15 to
50 years old.
● In Malaysia, it is estimated that more than 10,000 people have been diagnosed with SLE
over the past 30 years. However, the Malaysian SLE Association believes that there are
many more SLE sufferers in Malaysia who have not been diagnosed.
● In Asians: 30–50/100,000 individuals
● A prevalence of 43/100,000 individuals in Malaysia (2012)
○ Chinese (57/100,000)
○ Malays (33/100,000)
○ Indians (14/100,000)
● Ratio of SLE sufferers : In the West, among Afro-Carribeans 1 in 250-500 people
○ USA – 1 in 2,000 people
○ China – 1 in 1,000 people
EPIDEMIOLOGY
Aetiology
Nuratun ‘Aufa Binti Bahrul Kamil
20
22
20
22
AETIOLOGY
The exact etiology is unknown, but several predisposing factors have been
identified.
● Genetic predisposition
○ HLA-DR2 and HLA-DR3 are commonly present in individuals with SLE.
○ Genetic deficiency of classical pathway complement proteins (C1q, C2,
C4) in approx. 10% of affected individuals
● Hormonal factors: Hyperestrogenic states (e.g., due to oral contraceptive use,
postmenopausal hormonal therapy, endometriosis) are associated with an
increased risk of SLE.
20
22
20
22
AETIOLOGY
● Environmental factors
○ Cigarette smoking and silica exposure increase the risk of developing
SLE.
○ UV light and EBV infection may trigger disease flares, but there is
insufficient evidence on whether they cause SLE.
○ Drugs such as procainamide or hydralazine
20
22
20
22
Pathophysiology
20
22
20
22
Pathophysiology
● Autoantibody development: deficiency of classical complement proteins
(C1q, C4, C2) → failure of macrophages to phagocytose immune complexes
and apoptotic cell material (i.e., plasma and nuclear antigens) →
dysregulated, intolerant lymphocytes targeting normally hidden intracellular
antigens → autoantibody production (e.g., ANA, anti-dsDNA)
● Autoimmune reactions
○ Type III hypersensitivity (most common in SLE) → antibody-antigen
complex formation in microvasculature → complement activation and
inflammation → damage to skin, kidneys, joints, small vessels
○ Type II hypersensitivity → IgG and IgM antibodies directed against
antigens on cells (e.g., red blood cells) → cytopenia
20
22
20
22
20
22
20
22
20
22
20
22
Clinical Features
20
22
20
22
Clinical Features
SLE is a systemic disease characterized by phases of remission and relapse.
Some individuals only experience mild symptoms, while others experience
severe symptoms and rapid disease progression. SLE can affect any organ.
Common
● Constitutional: fatigue, fever, weight loss
● Joints (> 90% of cases)
○ Arthritis and arthralgia
○ Distal symmetrical polyarthritis
20
22
20
22
Clinical Features
● Skin (85% of cases)
○ Malar rash (butterfly rash)
○ Raynaud phenomenon
○ Photosensitivity → maculopapular rash
○ Discoid rash
○ Oral ulcers (usually painless)
○ Nonscarring alopecia
○ Periungual telangiectasia
20
22
20
22
20
22
20
22
COMPLICATION
Inflammation caused by lupus can affect many areas of the body, including:
● Kidneys. Lupus can cause serious kidney damage, and kidney failure is one of the
leading causes of death among people with lupus.
● Brain and central nervous system. If the brain is affected by lupus, the patient may
experience headaches, dizziness, behavior changes, vision problems, and even strokes
or seizures. Many people with lupus experience memory problems and may have
difficulty expressing their thoughts.
● Blood and blood vessels. Lupus may lead to blood problems, including a reduced
number of healthy red blood cells (anemia) and an increased risk of bleeding or blood
clotting. It can also cause inflammation of the blood vessels.
● Lungs. Having lupus increases the chances of developing an inflammation of the chest
cavity lining, which can make breathing painful. Bleeding into lungs and pneumonia
also are possible.
● Heart. Lupus can cause inflammation of the heart muscle, the arteries or heart
membrane. The risk of cardiovascular disease and heart attacks will increases.
► Having lupus also increases the risk of:
► Infection. People with lupus are more vulnerable to infection because
both the disease and its treatments can weaken the immune system.
► Cancer. Having lupus appears to increase your risk of cancer
► Bone tissue death. This occurs when the blood supply to a bone declines,
often leading to tiny breaks in the bone and eventually to the bone's
collapse.
► Pregnancy complications. Women with lupus have an increased risk of
miscarriage. Lupus increases the risk of high blood pressure during
pregnancy and preterm birth.
Investigation
Lab studies
Finding
1) Complete blood count
- Leukopenia - thrombocytopenia
- Normochromic normocytic anemia - increase in ESR
- +/- autoimmune hemolytic anemia - normal CRP
- Rh factor positive (30-50%) - False positive syphilis serology
- Complement level low (C3 and C4)
2) Autoantibody test
- Antinuclear antibody (ANA) is positive
- Anti ds-DNA -> double stranded DNA is positive (50%)
- Antiphospholipid antibodies (APLs) is positive
- Anti-Sm is positive of people with lupus (30%)
- Anti Ro (SSA) and anti-La (SSB) -> more common in Sjogren syndrome patient.
- Raised igG and IgM
-
3) Urine test
Microalbuminuria
Creatinine clearance increase
Urine microscopic : >5RBCs, >5 WBCs, cellular casts, spot proteins or spot creatinine
(proteinuria +)
4) Liver function test
Mildly elevated in acute SLE in response to NSAIDs
Creatine kinase levels may be elevated
5) Radiologic studies
Joint radiography
-> radiographic anomalies in SLE are periarticular osteopenia and soft tissue swelling without erosions
Chest X-ray CT scan
-> Fluid or inflammation in the lung -> Vasculitis, antiphospholipid, renal failure
-> right sided pleural effusion (yellow) -> Risk of developing pulmonary emboli
-> atelectasis with scarring in the left -> CT angiogram demonstrates filling defect in lung base (blue)
left anterior segmental arrow
CXR: monitor interstitial lung disease & assess pneumonitis, PE, alveolar hemorrhage
5) Radiologic studies
• Brain MRI
-> used to evaluate for CNS lupus white matter changes, vasculitis,
stroke
-> Axial, T2-weighted brain MRI demonstrate area of ischemic in the
right periventricular white matter
6) Joint effusion & CSF studies
• Arthrocentesis
-> cell count range <25% PMNs in noninflammatory effusions to >50% in
inflammatory effusions
-> gross appearance : straw colored or clear, viscosity
(noninflammatory cases) of fluids : yellow, viscosity (inflammatory
cases)
• Lumbar puncture
-> Elevated in nonspecific cell count found in CSF fluid
-> Proteins level increase with CNS lupus
-> Glucose decrease
7) Kidney biopsies
• Help in distinguishing renal lupus from renal vein thrombosis
which may be a complication of antiphospholipid antibody
syndrome
-> serum creatinine increased (absence of sepsis, hypovolemia,
medication)
-> spot protein: proteinuria >1.0g/24 hour
-> proteinuria (0.5g/>24 hours) with;
1) hematuria (>5 RBC/hpf) 2) cellular casts
MANAGEMENT
● Maintaining an active lifestyle to keep joints flexible and may prevent cardiovascular
complications. .
● Patients with lupus should avoid excessive sun exposure because the ultraviolet rays in
sunlight can cause a skin rash to flare, and may even trigger a more serious flare in the
disease itself. Wearing protective clothing (long sleeves, a big-brimmed hat) and using
sunscreen liberally when outdoors on a sunny day should protect against such
complications.
● Develop strategies for maintaining wellness. Wellness involves close attention to the
body, mind, and spirit. One of the primary goals of wellness for people with SLE is
coping with the stress of having a chronic disorder. Effective stress management varies
from person to person. Some approaches that may help include exercise, relaxation
techniques, and setting priorities for spending time and energy.
● Develop and maintain a good support system.A support system may include family,
friends, medical professionals, and support groups such as Persatuan SLE Malaysia.
● Learning more about SLE also helps. Studies have shown that patients who are
well-informed and participate actively in their own care tend to experience less pain,
make fewer visits to the doctor, and remain more active.
Non pharmalogical
1) NSAIDs
- Naproxen sodium
- Ibuprofen
-> treat pain, swelling and fever associated with lupus
-> stomach bleeding, kidney disease and increased risk of heart disease
2) Antimalarial drugs
- Hydroxychloroquine
-> used to treat malaria
-> affect the immune system and help decrease the risk of lupus flares.
-> stomach upset
-> damage to retina eyes (rarely)
3) Corticosteroid
- Prednisone
- Methylprednisolone*
- Triamcinolone (IM)
-> can counter the inflammation of lupus
-> high dose steroids often used to control serious disease that involves
kidneys and brain*
-> weight gain -> HTN
-> easy bruising -> diabetes
-> thinning bones -> risk of infection
4) Immunosuppressants
- Azathioprine - Cyclosporine
- Leflunomide - Mycophenolate
- Methotrexate
-> Drugs that suppress the immune system
-> increased risk of infection
-> liver damage
-> decreased fertility
-> increased risk of cancer
5) Biologics
- Belimumab (IV)
- Rituximab
-> Reduces lupus symptoms in people
-> useful in other medications that haven’t helped
-> Nausea, diarrhea, infections, depression worsening
-> allergic reactions to the intravenous and infections
● https://lupusmalaysia.org/what-is-sle#
● https://www.studocu.com/my/document/universiti-putra-malaysia/medical-doctor/sysytemic-lupus-erythem
atous/5712406
● https://emedicine.medscape.com/article/332244-overview#showall
●
References
THANK
YOU
20
22
20
22
Lupus clinical case
Awesome words
Lupus clinical case
Awesome words

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Systemic lupus
Systemic lupusSystemic lupus
Systemic lupus
 
Mixed connective tissue disorder
Mixed connective tissue disorderMixed connective tissue disorder
Mixed connective tissue disorder
 
Systemic lupus erythmatosus
Systemic lupus erythmatosusSystemic lupus erythmatosus
Systemic lupus erythmatosus
 
Sarcoidosis
SarcoidosisSarcoidosis
Sarcoidosis
 
Systemic lupus erythematosus2019
Systemic lupus erythematosus2019Systemic lupus erythematosus2019
Systemic lupus erythematosus2019
 
Systemic Lupus Erythematosus
Systemic Lupus ErythematosusSystemic Lupus Erythematosus
Systemic Lupus Erythematosus
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
 
Approach to anemia
Approach to anemiaApproach to anemia
Approach to anemia
 
Sle
SleSle
Sle
 
Systemic Lupus Erythematosus
Systemic Lupus ErythematosusSystemic Lupus Erythematosus
Systemic Lupus Erythematosus
 
Myocarditis. Cardiomyopathy
Myocarditis. CardiomyopathyMyocarditis. Cardiomyopathy
Myocarditis. Cardiomyopathy
 
Antiphospholipid syndrome
Antiphospholipid syndromeAntiphospholipid syndrome
Antiphospholipid syndrome
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
 
Systemic sclerosis
Systemic sclerosisSystemic sclerosis
Systemic sclerosis
 
Systemic lupus erythematosus
Systemic  lupus erythematosusSystemic  lupus erythematosus
Systemic lupus erythematosus
 
Minimal change disease
Minimal change diseaseMinimal change disease
Minimal change disease
 
Pediatric systemic lupus erythematosus
Pediatric systemic lupus erythematosusPediatric systemic lupus erythematosus
Pediatric systemic lupus erythematosus
 
Dermatomyositis
DermatomyositisDermatomyositis
Dermatomyositis
 
Antiphospholipid syndrome.pptx new
Antiphospholipid syndrome.pptx newAntiphospholipid syndrome.pptx new
Antiphospholipid syndrome.pptx new
 
Scleroderma
SclerodermaScleroderma
Scleroderma
 

Similar a SLE by Slidesgo.pdf

Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (SLE)Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (SLE)Arwa H. Al-Onayzan
 
Systemic Lupus Erythematoses
Systemic Lupus ErythematosesSystemic Lupus Erythematoses
Systemic Lupus Erythematosesdrangelosmith
 
systemiclupuserythematosus-180125101602.pdf
systemiclupuserythematosus-180125101602.pdfsystemiclupuserythematosus-180125101602.pdf
systemiclupuserythematosus-180125101602.pdfShinilLenin
 
Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (SLE)Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (SLE)yuyuricci
 
systemic lupuse rythematosus by formation of autoantibodies
systemic lupuse rythematosus by formation of autoantibodiessystemic lupuse rythematosus by formation of autoantibodies
systemic lupuse rythematosus by formation of autoantibodiesssuser45f282
 
systemiclupuserythematosus-180125101602.pptx
systemiclupuserythematosus-180125101602.pptxsystemiclupuserythematosus-180125101602.pptx
systemiclupuserythematosus-180125101602.pptxDinamGyatsoAadHenmoo
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosusShahdYr
 
Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)Anant Layall
 
Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus LupusNY
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosusAziz aziz
 
systemic lupus erythematosus
systemic lupus erythematosussystemic lupus erythematosus
systemic lupus erythematosusIAU Dent
 
SYSTEMIC LUPUS ERYTHEMATOSUS.pptx
SYSTEMIC LUPUS ERYTHEMATOSUS.pptxSYSTEMIC LUPUS ERYTHEMATOSUS.pptx
SYSTEMIC LUPUS ERYTHEMATOSUS.pptxA7mdM7moOd
 
Hematological disordres presentation.ppt
Hematological disordres presentation.pptHematological disordres presentation.ppt
Hematological disordres presentation.pptkitati1
 

Similar a SLE by Slidesgo.pdf (20)

Lupus overview for journalist
Lupus overview for journalistLupus overview for journalist
Lupus overview for journalist
 
Systemic Lupus Erythematosus
Systemic Lupus ErythematosusSystemic Lupus Erythematosus
Systemic Lupus Erythematosus
 
Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (SLE)Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (SLE)
 
Systemic Lupus Erythematoses
Systemic Lupus ErythematosesSystemic Lupus Erythematoses
Systemic Lupus Erythematoses
 
systemiclupuserythematosus-180125101602.pdf
systemiclupuserythematosus-180125101602.pdfsystemiclupuserythematosus-180125101602.pdf
systemiclupuserythematosus-180125101602.pdf
 
Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (SLE)Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus (SLE)
 
systemic lupuse rythematosus by formation of autoantibodies
systemic lupuse rythematosus by formation of autoantibodiessystemic lupuse rythematosus by formation of autoantibodies
systemic lupuse rythematosus by formation of autoantibodies
 
systemiclupuserythematosus-180125101602.pptx
systemiclupuserythematosus-180125101602.pptxsystemiclupuserythematosus-180125101602.pptx
systemiclupuserythematosus-180125101602.pptx
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
 
Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)Systemic lupus erythematosus (sle)
Systemic lupus erythematosus (sle)
 
Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus Get Into the Loop - Learn About Lupus
Get Into the Loop - Learn About Lupus
 
Systemic lupus erythematosus
Systemic lupus erythematosusSystemic lupus erythematosus
Systemic lupus erythematosus
 
systemic lupus erythematosus
systemic lupus erythematosussystemic lupus erythematosus
systemic lupus erythematosus
 
SYSTEMIC LUPUS ERYTHEMATOSUS.pptx
SYSTEMIC LUPUS ERYTHEMATOSUS.pptxSYSTEMIC LUPUS ERYTHEMATOSUS.pptx
SYSTEMIC LUPUS ERYTHEMATOSUS.pptx
 
Approach to sle
Approach to sleApproach to sle
Approach to sle
 
SLE
SLESLE
SLE
 
Hematological disordres presentation.ppt
Hematological disordres presentation.pptHematological disordres presentation.ppt
Hematological disordres presentation.ppt
 
lupus presentation final
lupus presentation finallupus presentation final
lupus presentation final
 
Rheumathoid arthritis
Rheumathoid arthritisRheumathoid arthritis
Rheumathoid arthritis
 
SLE.pptx
SLE.pptxSLE.pptx
SLE.pptx
 

Último

Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt downloadAnkitKumar311566
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxvirengeeta
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxDr.Nusrat Tariq
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformKweku Zurek
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfSreeja Cherukuru
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 

Último (20)

Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptx
 
epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
world health day presentation ppt download
world health day presentation ppt downloadworld health day presentation ppt download
world health day presentation ppt download
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in paharganj DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
POST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptxPOST NATAL EXERCISES AND ITS IMPACT.pptx
POST NATAL EXERCISES AND ITS IMPACT.pptx
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Glomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptxGlomerular Filtration rate and its determinants.pptx
Glomerular Filtration rate and its determinants.pptx
 
See the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy PlatformSee the 2,456 pharmacies on the National E-Pharmacy Platform
See the 2,456 pharmacies on the National E-Pharmacy Platform
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdfLippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
Lippincott Microcards_ Microbiology Flash Cards-LWW (2015).pdf
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 

SLE by Slidesgo.pdf

  • 3. ● Systemic Lupus Erythematosus (SLE), or lupus, is an autoimmune disorder where the immune system produces antibodies that attack the body’s own tissues, causing inflammation in many different parts of the body such as the skin, joints, brain, lungs, heart and kidneys. ● SLE predominantly affects women between 12 and 45 (frequently starting at childbearing age) INTRODUCTION
  • 5. ● Female:Male = 9:1 ● About 90% of SLE sufferers are women while about 10% are men and children. ● About 90% of women with SLE are in their childbearing years, within the range of 15 to 50 years old. ● In Malaysia, it is estimated that more than 10,000 people have been diagnosed with SLE over the past 30 years. However, the Malaysian SLE Association believes that there are many more SLE sufferers in Malaysia who have not been diagnosed. ● In Asians: 30–50/100,000 individuals ● A prevalence of 43/100,000 individuals in Malaysia (2012) ○ Chinese (57/100,000) ○ Malays (33/100,000) ○ Indians (14/100,000) ● Ratio of SLE sufferers : In the West, among Afro-Carribeans 1 in 250-500 people ○ USA – 1 in 2,000 people ○ China – 1 in 1,000 people EPIDEMIOLOGY
  • 6. Aetiology Nuratun ‘Aufa Binti Bahrul Kamil 20 22 20 22
  • 7. AETIOLOGY The exact etiology is unknown, but several predisposing factors have been identified. ● Genetic predisposition ○ HLA-DR2 and HLA-DR3 are commonly present in individuals with SLE. ○ Genetic deficiency of classical pathway complement proteins (C1q, C2, C4) in approx. 10% of affected individuals ● Hormonal factors: Hyperestrogenic states (e.g., due to oral contraceptive use, postmenopausal hormonal therapy, endometriosis) are associated with an increased risk of SLE. 20 22 20 22
  • 8. AETIOLOGY ● Environmental factors ○ Cigarette smoking and silica exposure increase the risk of developing SLE. ○ UV light and EBV infection may trigger disease flares, but there is insufficient evidence on whether they cause SLE. ○ Drugs such as procainamide or hydralazine 20 22 20 22
  • 10. Pathophysiology ● Autoantibody development: deficiency of classical complement proteins (C1q, C4, C2) → failure of macrophages to phagocytose immune complexes and apoptotic cell material (i.e., plasma and nuclear antigens) → dysregulated, intolerant lymphocytes targeting normally hidden intracellular antigens → autoantibody production (e.g., ANA, anti-dsDNA) ● Autoimmune reactions ○ Type III hypersensitivity (most common in SLE) → antibody-antigen complex formation in microvasculature → complement activation and inflammation → damage to skin, kidneys, joints, small vessels ○ Type II hypersensitivity → IgG and IgM antibodies directed against antigens on cells (e.g., red blood cells) → cytopenia 20 22 20 22
  • 14. Clinical Features SLE is a systemic disease characterized by phases of remission and relapse. Some individuals only experience mild symptoms, while others experience severe symptoms and rapid disease progression. SLE can affect any organ. Common ● Constitutional: fatigue, fever, weight loss ● Joints (> 90% of cases) ○ Arthritis and arthralgia ○ Distal symmetrical polyarthritis 20 22 20 22
  • 15. Clinical Features ● Skin (85% of cases) ○ Malar rash (butterfly rash) ○ Raynaud phenomenon ○ Photosensitivity → maculopapular rash ○ Discoid rash ○ Oral ulcers (usually painless) ○ Nonscarring alopecia ○ Periungual telangiectasia 20 22 20 22
  • 17. COMPLICATION Inflammation caused by lupus can affect many areas of the body, including: ● Kidneys. Lupus can cause serious kidney damage, and kidney failure is one of the leading causes of death among people with lupus. ● Brain and central nervous system. If the brain is affected by lupus, the patient may experience headaches, dizziness, behavior changes, vision problems, and even strokes or seizures. Many people with lupus experience memory problems and may have difficulty expressing their thoughts. ● Blood and blood vessels. Lupus may lead to blood problems, including a reduced number of healthy red blood cells (anemia) and an increased risk of bleeding or blood clotting. It can also cause inflammation of the blood vessels. ● Lungs. Having lupus increases the chances of developing an inflammation of the chest cavity lining, which can make breathing painful. Bleeding into lungs and pneumonia also are possible. ● Heart. Lupus can cause inflammation of the heart muscle, the arteries or heart membrane. The risk of cardiovascular disease and heart attacks will increases.
  • 18. ► Having lupus also increases the risk of: ► Infection. People with lupus are more vulnerable to infection because both the disease and its treatments can weaken the immune system. ► Cancer. Having lupus appears to increase your risk of cancer ► Bone tissue death. This occurs when the blood supply to a bone declines, often leading to tiny breaks in the bone and eventually to the bone's collapse. ► Pregnancy complications. Women with lupus have an increased risk of miscarriage. Lupus increases the risk of high blood pressure during pregnancy and preterm birth.
  • 20. Lab studies Finding 1) Complete blood count - Leukopenia - thrombocytopenia - Normochromic normocytic anemia - increase in ESR - +/- autoimmune hemolytic anemia - normal CRP - Rh factor positive (30-50%) - False positive syphilis serology - Complement level low (C3 and C4) 2) Autoantibody test - Antinuclear antibody (ANA) is positive - Anti ds-DNA -> double stranded DNA is positive (50%) - Antiphospholipid antibodies (APLs) is positive - Anti-Sm is positive of people with lupus (30%) - Anti Ro (SSA) and anti-La (SSB) -> more common in Sjogren syndrome patient. - Raised igG and IgM -
  • 21. 3) Urine test Microalbuminuria Creatinine clearance increase Urine microscopic : >5RBCs, >5 WBCs, cellular casts, spot proteins or spot creatinine (proteinuria +) 4) Liver function test Mildly elevated in acute SLE in response to NSAIDs Creatine kinase levels may be elevated
  • 22. 5) Radiologic studies Joint radiography -> radiographic anomalies in SLE are periarticular osteopenia and soft tissue swelling without erosions Chest X-ray CT scan -> Fluid or inflammation in the lung -> Vasculitis, antiphospholipid, renal failure -> right sided pleural effusion (yellow) -> Risk of developing pulmonary emboli -> atelectasis with scarring in the left -> CT angiogram demonstrates filling defect in lung base (blue) left anterior segmental arrow CXR: monitor interstitial lung disease & assess pneumonitis, PE, alveolar hemorrhage
  • 23. 5) Radiologic studies • Brain MRI -> used to evaluate for CNS lupus white matter changes, vasculitis, stroke -> Axial, T2-weighted brain MRI demonstrate area of ischemic in the right periventricular white matter 6) Joint effusion & CSF studies • Arthrocentesis -> cell count range <25% PMNs in noninflammatory effusions to >50% in inflammatory effusions -> gross appearance : straw colored or clear, viscosity (noninflammatory cases) of fluids : yellow, viscosity (inflammatory cases) • Lumbar puncture -> Elevated in nonspecific cell count found in CSF fluid -> Proteins level increase with CNS lupus -> Glucose decrease
  • 24. 7) Kidney biopsies • Help in distinguishing renal lupus from renal vein thrombosis which may be a complication of antiphospholipid antibody syndrome -> serum creatinine increased (absence of sepsis, hypovolemia, medication) -> spot protein: proteinuria >1.0g/24 hour -> proteinuria (0.5g/>24 hours) with; 1) hematuria (>5 RBC/hpf) 2) cellular casts
  • 25.
  • 27. ● Maintaining an active lifestyle to keep joints flexible and may prevent cardiovascular complications. . ● Patients with lupus should avoid excessive sun exposure because the ultraviolet rays in sunlight can cause a skin rash to flare, and may even trigger a more serious flare in the disease itself. Wearing protective clothing (long sleeves, a big-brimmed hat) and using sunscreen liberally when outdoors on a sunny day should protect against such complications. ● Develop strategies for maintaining wellness. Wellness involves close attention to the body, mind, and spirit. One of the primary goals of wellness for people with SLE is coping with the stress of having a chronic disorder. Effective stress management varies from person to person. Some approaches that may help include exercise, relaxation techniques, and setting priorities for spending time and energy. ● Develop and maintain a good support system.A support system may include family, friends, medical professionals, and support groups such as Persatuan SLE Malaysia. ● Learning more about SLE also helps. Studies have shown that patients who are well-informed and participate actively in their own care tend to experience less pain, make fewer visits to the doctor, and remain more active. Non pharmalogical
  • 28.
  • 29. 1) NSAIDs - Naproxen sodium - Ibuprofen -> treat pain, swelling and fever associated with lupus -> stomach bleeding, kidney disease and increased risk of heart disease 2) Antimalarial drugs - Hydroxychloroquine -> used to treat malaria -> affect the immune system and help decrease the risk of lupus flares. -> stomach upset -> damage to retina eyes (rarely)
  • 30. 3) Corticosteroid - Prednisone - Methylprednisolone* - Triamcinolone (IM) -> can counter the inflammation of lupus -> high dose steroids often used to control serious disease that involves kidneys and brain* -> weight gain -> HTN -> easy bruising -> diabetes -> thinning bones -> risk of infection 4) Immunosuppressants - Azathioprine - Cyclosporine - Leflunomide - Mycophenolate - Methotrexate -> Drugs that suppress the immune system -> increased risk of infection -> liver damage -> decreased fertility -> increased risk of cancer
  • 31. 5) Biologics - Belimumab (IV) - Rituximab -> Reduces lupus symptoms in people -> useful in other medications that haven’t helped -> Nausea, diarrhea, infections, depression worsening -> allergic reactions to the intravenous and infections
  • 33. THANK YOU 20 22 20 22 Lupus clinical case Awesome words Lupus clinical case Awesome words